Imaging Endpoints Founder Discusses Role in PharmaCyte Biotech’s Unique Approach to Pancreatic Cancer for Upcoming Clinical...
October 05 2015 - 9:25AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, released today the third in a series of
articles that will serve to educate the public on its technology
and how it is used in the treatment of advanced pancreatic cancer.
This latest article is written by Dr. Ronald L. Korn, MD, Ph.D.,
who is the Founder, Chairman and Chief Medical Officer of Imaging
Endpoints in Scottsdale, Arizona. Imaging Endpoints is the company
that will perform the radiologic imaging that will be required for
PharmaCyte Biotech’s upcoming Phase 2b clinical trial in pancreatic
cancer.
The article titled, “Imaging to Cure Cancer:
Valuable Contribution of Radiology for Clinical Trial Success,”
highlights the role Imaging Endpoints will play in PharmaCyte
Biotech’s pivotal Phase 2b clinical trial. The article discusses:
(i) the use of radiologic imaging to detect, track and confirm
treatment responses in clinical trials; (ii) the unique aspects and
opportunities for Cell-in-a-Box® to treat pancreatic cancer; and
(iii) PharmaCyte Biotech’s upcoming Phase 2b clinical trial.
In the article, Dr. Korn explains, “PharmaCyte
Biotech’s Cell-in-A-Box® technology provides a new approach to
treat this deadly disease (pancreatic cancer) by potentially
reducing the pancreatic tumor burden enough to offer patients a
chance at a surgical cure. However, knowing whether treatment is
working or not is one of the single most critical elements for
delivering the right care to patients at the right time.
Determining this, of course, is not a simple task. It requires both
laboratory and radiology confirmation that a treatment is making a
difference.”
PharmaCyte Biotech’s Chief Operating Officer, Dr.
Gerald W. Crabtree, commented, “Dr. Korn’s comprehensive article is
extremely informative. Among the many important factors discussed
in the article, Dr. Korn emphasizes that the radiologic imaging
must be consistent among all study sites and the subsequent
analyses of all of the radiologic images must be centralized. The
types of advanced radiologic analyses that Dr. Korn and his
colleagues can provide will give us the most definitive radiologic
data possible. From the in-depth nature of Dr. Korn’s article and
the knowledge that his company has performed such advanced analyses
for over 100 clinical trials in the U.S. and throughout the world,
it is evident that PharmaCyte Biotech could not have chosen a
better company than Imaging Endpoints for the radiology studies
that will be part of our Phase 2b clinical trial.”
Read Dr. Korn’s exclusive article on Imaging to
Cure Cancer and his company’s role in PharmaCyte’s Phase 2b
clinical trial at:
http://www.pharmacytebiotech.com/imaging-to-cure-cancer-valuable-contribution-of-radiology-for-clinical-trial-success
About PharmaCyte BiotechPharmaCyte
Biotech is a clinical stage biotechnology company focused on
developing and preparing to commercialize treatments for cancer and
diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as “Cell-in-a-Box®”. This unique and
patented technology will be used as a platform upon which
treatments for several types of cancer and diabetes are being
developed.
PharmaCyte Biotech’s treatment for cancer involves
encapsulating genetically modified live cells capable of converting
an inactive chemotherapy drug (ifosfamide) into its active or
“cancer-killing” form. These encapsulated live cells are placed as
close to a cancerous tumor as possible. Once implanted in a
patient, ifosfamide is given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been placed. When ifosfamide, which is
normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the drug takes place at the
source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte Biotech is developing a treatment for Type 1
diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech
plans to encapsulate a human cell line which has been genetically
engineered to produce, store and secrete insulin at levels in
proportion to the levels of blood sugar in the human body. The
encapsulation will be done using the
Cell-in-a-Box® technology.
Safe Harbor This press release may
contain forward-looking statements regarding PharmaCyte Biotech and
its future events and results that involve inherent risks and
uncertainties. The words "anticipate," "believe," "estimate,"
"expect," "intend," "plan" and similar expressions, as they relate
to PharmaCyte Biotech or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte Biotech, could cause actual
results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte Biotech’s
intellectual property and PharmaCyte Biotech’s continued ability to
raise capital. PharmaCyte Biotech does not assume any obligation to
update any of these forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com